Overview
- STAT reported on Tuesday that the FDA and Eli Lilly approved one compassionate‑use request in April for retatrutide for an unnamed 79‑year‑old patient, and multiple outlets corroborated that reporting.
- A senior NIH clinician, Ranganath Muniyappa, submitted the request citing refractory obesity with obstructive sleep apnea and pulmonary hypertension and noting prior limited benefit from tirzepatide.
- The White House issued an explicit denial through spokesperson Kush Desai saying the application was not for President Trump after reporters asked because the patient’s age matched the president’s.
- Bioethicists and obesity clinicians told reporters that using expanded access for a weight‑loss drug is highly unusual, and critics flagged that Eli Lilly’s only public notice was a terse June 1 ClinicalTrials.gov posting.
- Beyond the mystery of the recipient, the episode is likely to increase scrutiny of how expanded access decisions are made, who can secure early doses of high‑demand investigational drugs, and whether regulators or companies should disclose more about such exceptions.